Table 2.

Changes in soluble checkpoint proteins and plasma cytokines before and after IMRT in NPC.

	Pre-IMRT radiotherapy	Post-IMRT radiotherapy	Control	p1	p2	p3
BTLA	77.0±59.6	76.5±58.9	344.1±102.3	0.948	≤0.001	≤0.001
GITR	12.1±16.0	11.5±15.9	13.3±7.4	0.709	0.022	0.009
HVEM	4.1±11.6	7.7±21.3	94.0±18.3	0.325	≤0.001	≤0.001
IDO	14.3±16.7	14.7±18.5	13.9±5.0	0.737	0.084	0.019
LAG-3	121.4±79.5	79.7±45.5	64.8±28.6	≤0.00	≤0.001	0.087
sPD-1	12.4±7.8	30.0±20.6	69.7±38.8	≤0.001	≤0.001	≤0.001
sPD-L1	4.7±3.2	11.1±3.3	13.7±5.6	≤0.001	≤0.001	0.017
sPD-L2	1571.6±719.3	1463.3±797.8	2901.9±1026.1	0.388	≤0.001	≤0.001
TIM-3	1702.8±867.8	2643.3±1243.8	2005.6±633.4	≤0.001	0.087	0.005
CD28	58.6±98.6	53.2±83.3	292.0±76.2	0.315	≤0.001	≤0.001
CD80	99.9±114.4	92.6±110.6	526.4±454.5	0.191	≤0.001	≤0.001
CD137	8.8±29.4	9.6±35.9	48.8±38.1	0.715	≤0.001	≤0.001
CD27	358.7±377.0	369.9±355.4	480.3±368.7	0.731	0.049	0.004
CD152	18.0±20.5	17.6±20.6	21.7±9.8	0.386	0.002	0.003
IFN-γ	65.6±37.4	15.2±8.8	29.2±16.9	≤0.001	≤0.001	≤0.001
IL-12p70	6.3±0.6	3.7±1.2	3.5±0.8	≤0.001	≤0.001	0.607
IL-13	14.0±12.3	17.7±9.8	14.7±8.9	0.154	0.566	0.070
IL-1β	6.6±6.7	6.1±5.1	3.1±5.2	0.005	0.002	≤0.001
IL-2	22.8±23.2	19.6±14.0	10.2±15.9	0.563	0.027	≤0.001
IL-4	14.2±7.8	11.2±5.0	16.7±5.7	0.782	0.119	≤0.001
IL-5	13.5±7.9	7.2±6.0	7.2±3.3	≤0.001	≤0.001	0.036
IL-6	86.2±111.7	15.3±11.2	9.0±17.6	≤0.001	≤0.001	≤0.001
TNF-α	40.8±40.7	19.0±8.9	9.6±11.8	≤0.001	≤0.001	≤0.001
GM-CSF	12.4±15.1	13.5±10.9	11.1±12.0	0.417	0.319	0.240
IL-18	57.6±79.1	49.8±28.0	63.4±42.5	0.405	0.076	0.104
IL-10	12.6±19.0	3.5±3.6	0.8±0.2	≤0.001	≤0.001	≤0.001
IL-17A	9.3±9.3	1.9±1.5	1.6±1.1	≤0.001	≤0.001	0.597
IL-21	6.7±16.4	6.3±7.5	4.1±5.7	0.208	0.182	0.029
IL-22	153.0±102.6	81.6±59.3	75.0±20.9	≤0.001	≤0.001	0.171
IL-23	14.3±6.0	17.0±18.4	15.6±3.4	0.904	0.127	0.024
IL-27	15.1±28.6	12.0±11.0	23.1±20.1	0.517	≤0.001	≤0.001
IL-9	8.3±7.0	5.5±3.9	14.8±11.8	0.209	≤0.001	≤0.001

p1, pre-IMRT and post-IMRT.

p2, pre-IMRT and control.

p3, post-IMRT and control.